Frequently asked questions

Answers to the questions we are asked most often.

Getting started

Your data and who can see it

Funding and reporting

About Molecule

Molecule is a first mover and market leader in the Decentralized Science ecosystem, operating since 2019.

Molecule founded leading DeSci organizations BIO Protocol, VitaDAO and pump.science. Collectively, we’ve received backing from Northpond Ventures, Pfizer Ventures, Balaji Srinivasan, Yzi Labs, Shine Capital, Maelstrom, and more.

Our novel model has been published in Nature Biotechnology and featured in the Stanford Law Review and Forbes.

More questions

No. Tokens are not US qualified stablecoins or bank deposits, and are not insured by the FDIC, SIPC, or any government agency. Equity represents ownership in a private company and is not insured. Both tokens and equity may lose value, and you may lose your entire equity investment. Customer tokens may be exposed to custody, cybersecurity, counterparty, smart-contract, and insolvency risks.

No. Molecule AG is not a registered broker-dealer or investment adviser with the U.S. Securities and Exchange Commission, any state securities regulator, or FINRA. Molecule operates a technology platform that facilitates transactions between projects and participants. Molecule does not solicit securities transactions, provide investment advice, or receive transaction-based compensation for securities-related activities.

Molecule AG may receive compensation from project fees, subscription fees, or other arrangements with projects listed on the platform. These arrangements create conflicts of interest because they may give Molecule a financial incentive concerning which projects are displayed or promoted on the platform. Molecule does not receive transaction-based compensation for securities-related activities. See our Fees and Conflicts Disclosure for additional information.

No. Tokens are never converted to equity under any circumstances. The tokens provide the community association and blockchain administrative functions only. You can hold and use your tokens without ever applying for equity. The equity track exists as an option for those who want it, and would use the blockchain infrastructure to exercise their equity rights if separately obtained.

Equity issued through Coin-to-Company may provide U.S. tax advantages depending on the shareholder's circumstances and the structure of the issuing company. Shares may be eligible for exclusion of federal capital gains under Internal Revenue Code Section 1202 (Qualified Small Business Stock), subject to satisfaction of issuer-level, shareholder-level, holding-period, active-business, redemption, and gain-limitation requirements.

The potential exclusion is 50% after three years, 75% after four years, and 100% after five years, subject to a per-issuer limitation of the greater of $15 million of eligible gain or ten times qualifying basis. Tax treatment is highly fact-specific and jurisdiction-dependent. State tax treatment varies and may differ from federal treatment. Consult a qualified tax advisor to understand the tax consequences applicable to your situation before participating.